TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02473224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.2 Challenge
Description: GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.2 Challenge
Description: GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.2 Challenge
Description: GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GII.2 Challenge
Description: GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10\^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10\^2 GEC or 1.2 x10\^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10\^1 GEC, 1.2 x 10\^2 GEC, 1.2 x 10\^3 GEC, 1.2 x 10\^5 GEC, or 1.2 x 10\^6 GEC, or 1.2 GEC x 10\^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: 80 ml of sterile water for oral administration
Study: NCT03511300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Setting Instructions
Description: In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Instructions
Description: Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Instructions
Description: Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
Study: NCT02167724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bucco-dental examination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and social questionnaire
Study: NCT01999348

Intervention type: DRUG
Intervention: Fixed Combination Bimatoprost and Timolol
Description: Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
Study: NCT01464814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic plus fish oil capsule
Description: Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil capsule
Description: Fish oil capsule, T.I.D., for seven (7) days
Study: NCT03436147

Intervention type: OTHER
Intervention: POP-Q
Description: Pelvic Organ Prolapse Quantification

Intervention type: OTHER
Intervention: POP-Q
Description: Pelvic Organ Prolapse Quantification
Study: NCT03782844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple CPAP+Conventional fixed CPAP
Description: Patients used simple CPAP and conventional fixed CPAP during overnight polysomnography.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple CPAP + Auto CPAP
Description: Patients used simple CPAP and Auto CPAP during overnight polysomnography.
Study: NCT04283357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Short Foot Exercises

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Exercise with virtual reality
Study: NCT02620735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fit bit Device
Description: Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Only
Description: 12 week exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: 12 week exercise program
Study: NCT02601430

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOLD-MRI
Description: A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
Study: NCT00780767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANGIOJET RHEOLYTIC THROMBECTOMY
Description: The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
Study: NCT01434628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
Study: NCT00740441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1411
Description: AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
Study: NCT02788032

Intervention type: OTHER
Group type: OTHER
Intervention: EnergieShake oral supplement
Description: The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
Study: NCT02929160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Description: Percutaneous nephrostomy tube insertion under radiological guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde ureteric JJ stent
Description: Retrograde ureteric JJ stent insertion using cystoscopy
Study: NCT00606411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topiramate or Placebo
Description: 25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate or Placebo
Description: 25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
Study: NCT02620735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connected Wellness HealthCoach Software
Description: Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: 10 over the phone health coaching sessions.
Study: NCT04955496

Intervention type: PROCEDURE
Intervention: Enhanced recovery after surgery
Description: ERAS management includes 3 parts: (1) Preoperative analgesia and airway evaluation. (2) The protection and reconstruction of the musculo-ligamentous complex during the surgery, the safe intubation, and the local infiltration anesthesia during surgery. (3) Collar free, multimodal analgesia, airway management, and early recovery after surgery.
Study: NCT01057862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Targeted dosage of 50mg PO daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills daily PO
Study: NCT03759028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Study: NCT00156013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLOFARABINE
Description: 4 mg/m\^2 days 1-5 of every cycle for a maximum of 6 cycles
Study: NCT04287439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Patients will receive a training session for progressive muscle relaxation exercise They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: Patients will receive a training session for mindfulness meditation. They will practice it daily at their home during 12 weeks. Patients will be called daily to ensure that patients perform the intervention according to the study protocol, and to assess their study-adherence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention matched control
Description: Patients will receive a training session focusing on focusing on the anatomy and physiological functions of the pancreas, general information about type 2 diabetes including signs, complication, and treatment methods
Study: NCT01302691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)
Description: One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan potassium
Description: One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
Study: NCT04692831

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 89Zr-ss-pertuzumab PET/CT
Description: Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 89Zr-ss-pertuzumab PET/CT
Description: Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.
Study: NCT03244384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation
Study: NCT01302691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-0954E
Description: One tablet, containing placebo, orally, once daily, for 8 weeks.
Study: NCT00628537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION stimulation
Description: BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises.
Study: NCT01302691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to losartan potassium
Description: One tablet, containing placebo, orally, once daily, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to amlodipine besylate
Description: One capsule, containing placebo, orally, once daily, for 8 weeks.
Study: NCT02177812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
Study: NCT02005783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBD
Description: DBD:one dose of medicine twice per day, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin:90mg/m2, d1, q3w\*4
Study: NCT00628537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BION stimulation
Description: BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BION stimulation
Description: BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises.
Study: NCT03244384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo a CT scan
Study: NCT02444923

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)
Description: Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)
Description: Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)
Description: The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)
Description: The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
Study: NCT03463382

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane block will be administered under general anesthesia before the surgery
Study: NCT02005783

Intervention type: DRUG
Group type: OTHER
Intervention: Epirubicin
Description: Epirubicin:90mg/m2, d1, q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide:600mg/m2, d1, q3w\*4

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Cyclophosphamide:600mg/m2, d1, q3w\*4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel:75mg/m2, d1, q3w\*4

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel:75mg/m2, d1, q3w\*4
Study: NCT04010162

Intervention type: OTHER
Intervention: Mesh debate awareness survey
Description: A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute

Intervention type: OTHER
Intervention: Mesh debate awareness survey
Description: A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute

Intervention type: OTHER
Intervention: Mesh debate awareness survey
Description: A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute

Intervention type: OTHER
Intervention: Mesh debate awareness survey
Description: A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute
Study: NCT03447821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Rifamycin SV dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 mg Rifamycin SV dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200 mg Rifamycin SV dosage
Study: NCT03244384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Urography
Description: Undergo a CT urography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT Urography
Description: Undergo a CT urography
Study: NCT03463382

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block will be administered under general anesthesia before the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Block Drug)
Description: 0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
Study: NCT02791360

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI